SecBot SecBot

PNMXO

PUBLIC SERVICE CO OF NEW MEXICO
OTC· Electric & Other Services Combined· Inc. NM· CIK 0000081023 Traditional Energy
$69.25 +0.00 (+0.00%)
Oct 26 4:00 PM ET · prev $69.25
1 year
−13.4%
from $80.00 · Oct 27
30 days
−5.1%
from $73.00
52-week range
$67.01–85.50
−19% from high · low Oct 21
Avg volume 20D
89
Oct 16 spike 951
Short interest
🔒 Subscribers only
Filing reports
1
analyzed by SecBot
SecBot read MIXED 1 report · latest
Balance 0 bearish · 0 bullish · 1 neutral oldest → newest, height = score
Avg score ·High conf. 1/1
Strongest NEUTRAL The SEC has declared effective a registration statement for Public Service Co of New Mexico, allowing the…
All reports →

Price

Daily candles with volume.

Signal stack

Where each data set points today.

  • TrendDOWNTREND

    4% below its 50-day average. New closing low $67.01 on Oct 22.

Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Apr 24, 2026 Drug approval
EMA: Human medicines European public assessment report (EPAR): Cenrifki, tolebrutinib, Status: Opinion
Human medicines European public assessment report (EPAR): Cenrifki, tolebrutinib, Status: Opinion
Feb 26, 2026 SEC
The SEC has declared effective a registration statement for Public Service Co of New Mexico, allowing the company to…
EFFECT — Impact 4/10
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Apr 24, 2026
Drug approval
EMA: Human medicines European public assessment report (EPAR): Cenrifki, tolebrutinib, Status: Opinion
Human medicines European public assessment report (EPAR): Cenrifki, tolebrutinib, Status: Opinion
Apr 24, 2026
Drug approval
EMA: Human medicines European public assessment report (EPAR): Itvisma, onasemnogene abeparvovec, Status: Opinion
Human medicines European public assessment report (EPAR): Itvisma, onasemnogene abeparvovec, Status: Opinion
Mar 27, 2026
Drug approval
EMA: Human medicines European public assessment report (EPAR): Adstiladrin, nadofaragene firadenovec, Status: Opinion
Human medicines European public assessment report (EPAR): Adstiladrin, nadofaragene firadenovec, Status: Opinion
Mar 27, 2026
Drug approval
EMA: Human medicines European public assessment report (EPAR): Zepzelca, lurbinectedin, Status: Opinion
Human medicines European public assessment report (EPAR): Zepzelca, lurbinectedin, Status: Opinion
Mar 27, 2026
Drug approval
EMA: Human medicines European public assessment report (EPAR): Joenja, leniolisib, Status: Opinion
Human medicines European public assessment report (EPAR): Joenja, leniolisib, Status: Opinion

Earnings setup

Estimates
PeriodEPS est.Range30D rev.Revenue
Current Q———$0.00
Next Q———$0.00
Current FY———$0.00
Next FY———$0.00

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short

SecBot reports

1 filing · 0 bullish · 0 bearish · 1 neutral
All PNMXO filing & press-release reports (1)